• Nur Fadilatul Ilmiyah Mathematics Education Study Program, Faculty of Tarbiyah, IAIN Kediri, Indonesia
  • Salma Zahrotun Nihayah Al Hasani Mathematics Education Study Program, Faculty of Tarbiyah, IAIN Kediri, Indonesia
  • Della Renaningtyas Mathematics Education Study Program, Faculty of Tarbiyah, IAIN Kediri, Indonesia
Keywords: SAW, TOPSIS, Borda Count, Convalescent Plasma Donors


Convalescent Plasma Therapy (CPT) is an additional therapy to increase the chances of recovery for patients infected with COVID-19. CPT is carried out by giving blood plasma from COVID-19 survivors to COVID-19 patients. Not all survivors of COVID-19 can become plasma donors. Several criteria must be met. Therefore, selecting and sequencing potential plasma donors can be considered an act of decision-making. This research aims to provide an overview of the application of the SAW-TOPSIS combination and the Borda Count method in selecting and ranking potential plasma donor candidates. The criteria for prospective plasma donors are limited to six aspects, namely age, weight, history of blood transfusion, gender, pregnancy status, history of being infected with COVID-19, and history of previous illnesses. Data was taken from ten COVID-19 survivors to illustrate the application of the three methods. The data is taken from a questionnaire distributed via Google Forms. This research was carried out through 3 stages: applying the SAW method, the TOPSIS method, and the Borda Count method. From the calculated results, P06 was the most potential plasma donor candidate, followed by P03, P09, P02, and P04.


Download data is not yet available.


A. E. Gorbalenya et al., “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2,” Nat. Microbiol., vol. 5, no. 4, pp. 536–544, 2020, doi: 10.1038/s41564-020-0695-z.

A. Vitiello, F. Ferrara, M. Boccellino, A. M. Auti, and M. Di Domenico, “Advances in the Omicron variant development,” J. Intern. Med., vol. 2, pp. 81–90, 2022, doi: 10.1111/joim.13478.

S. K. Das, “The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19),” Indian J. Clin. Biochem., vol. 35, no. 4, pp. 385–396, 2020, doi: 10.1007/s12291-020-00919-0.

E. Mathieu et al., “Coronavirus Pandemic (COVID-19),”, 2020.

S. J. Gao, H. Guo, and G. Luo, “Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert!,” J. Med. Virol., vol. 94, no. 4, pp. 1255–1256, 2022, doi: 10.1002/jmv.27491.

A. Susilo et al., “Mutasi dan Varian Coronavirus Disease 2019 (COVID-19): Tinjauan Literatur Terkini,” J. Penyakit Dalam Indones., vol. 9, no. 1, p. 59, 2022, doi: 10.7454/jpdi.v9i1.648.

S. Thakur et al., “SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines,” Front. Med., vol. 9, no. February, 2022, doi: 10.3389/fmed.2022.815389.

E. M. Kurniawati et al., “Effectiveness of convalescent plasma therapy for COVID-19 patients infected with variants of concerns,” Anaesthesia, Pain Intensive Care, vol. 26, no. 4, pp. 535–545, 2022, doi: 10.35975/apic.v26i4.1962.

O. Garraud, “Use of convalescent plasma in Ebola virus infection,” Transfus. Apher. Sci., vol. 56, no. 1, pp. 31–34, 2017, doi: 10.1016/j.transci.2016.12.014.

D. S. Hui, N. Lee, P. K. Chan, and J. H. Beigel, “The role of adjuvant immunomodulatory agents for treatment of severe influenza,” Antiviral Res., vol. 150, no. December 2017, pp. 202–216, 2018, doi: 10.1016/j.antiviral.2018.01.002.

J. Mair-Jenkins et al., “The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis,” J. Infect. Dis., vol. 211, no. 1, pp. 80–90, 2015, doi: 10.1093/infdis/jiu396.

Y. M. Arabi et al., “Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia,” Emerg. Infect. Dis., vol. 22, no. 9, pp. 1554–1561, 2016, doi: 10.3201/eid2209.151164.

N. Samad et al., “Convalescent plasma therapy for management of COVID-19: Perspectives and deployment in the current global pandemic,” Risk Manag. Healthc. Policy, vol. 13, pp. 2707–2728, 2020, doi: 10.2147/RMHP.S281388.

M. J. Joyner et al., “Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients,” Mayo Clin. Proc., vol. 95, no. 9, pp. 1888–1897, 2020, doi: 10.1016/j.mayocp.2020.06.028.

L. Li et al., “Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation,” Transfusion, vol. 60, no. 8, pp. 1765–1772, 2020, doi: 10.1111/trf.15918.

F. Irfan, “Seputar Plasma Konvalesen,”, 2021.

L. W. Santosa, “Anda harus sehat bila ingin jadi pendonor plasma konvalesen,”, 2021.

D. A. Pertiwi, B. Daniawan, and Y. Gunawan, “Analysis And Design of Decision Support System in Major Assignment at Buddhi High School Using AHP and SAW Methods,” J. Tech-E, vol. 3, no. 1, p. 13, 2019, doi: 10.31253/te.v3i1.138.

S. S. Putro, F. Adiputra, E. M. S. Rochman, A. Rachmad, M. A. Syakur, and S. B. Seta, “Comparison of saw and wp methods to determine the best agricultural land,” Commun. Math. Biol. Neurosci., vol. 2021, pp. 1–15, 2021, doi: 10.28919/cmbn/5820.

D. W. T. Putra and A. A. Punggara, “Comparison Analysis of Simple Additive Weighting (SAW) and Weigthed Product (WP) in Decision Support Systems,” MATEC Web Conf., vol. 215, pp. 1–5, 2018, doi: 10.1051/matecconf/201821501003.

A. Hamid et al., “Determining basic food quality using SAW,” Int. J. Eng. Technol., vol. 7, no. 4, pp. 3548–3555, 2018, doi: 10.14419/ijet.v7i4.18835.

A. Afshari, M. Mojahed, and R. Yusuff, “Simple additive weighting approach to personnel selection problem,” Int. J. Innov. Manag. Technol., vol. 1, no. 5, pp. 511–515, 2010, [Online]. Available:

A. Kumar, V. Swaroop, A. K. Sharma, S. P. Lai, and V. Bist, “Sustainable raw material selection for pulp and paper using SAW multiple criteria decision making design,” IPPTA Q. J. Indian Pulp Pap. Tech. Assoc., vol. 27, no. 1, pp. 67–76, 2015.

İ. Durak, H. M. Arslan, and Y. Özdemir, “Application of AHP–TOPSIS methods in technopark selection of technology companies: Turkish case,” Technol. Anal. Strateg. Manag., vol. 34, no. 10, pp. 1109–1123, 2022, doi: 10.1080/09537325.2021.1925242.

E. Roszkowska, “Multi-Criteria Decision Making Models by Applying the Topsis Method to Crisp and Interval Data,” in Multiple Criteria Decision Making ’10-11, 2011, pp. 200–230.

M. Collan, M. Fedrizzi, and P. Luukka, “A multi-expert system for ranking patents: An approach based on fuzzy pay-off distributions and a TOPSIS-AHP framework,” Expert Syst. Appl., vol. 40, no. 12, pp. 4749–4759, 2013, doi: 10.1016/j.eswa.2013.02.012.

S. A. Lusinia, N. Rahmansyah, and A. I. Jamhur, “Determining the feasibility of coconut coir suppliers using a combination of decision support system methods,” Int. J. Dyn. Enginering Sci., vol. 7, no. 2, pp. 178–181, 2022.

A. T. Eshlaghy and E. N. Farokhi, “Measuring the Importance and the Weight of Decision Makers in the Criteria Weighting Activities of Group Decision Making Process,” Am. J. Sci. Res., vol. 24, no. 24, pp. 6–12, 2011.

F. S. Loffredo et al., “Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy,” Cell, vol. 153, no. 4, pp. 828–839, 2013, doi: 10.1016/j.cell.2013.04.015.

X. Zeng et al., “Association between recipient survival and blood donor age after blood transfusion in a surgery intensive care unit: a multicenter randomized controlled trial study protocol,” Trials, vol. 21, no. 1, pp. 1–9, 2020, doi: 10.1186/s13063-020-04452-6.

S. A. Villeda et al., “Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice,” Nat. Med., vol. 20, no. 6, pp. 659–663, 2014, doi: 10.1038/nm.3569.

G. S. Baht et al., “Exposure to a youthful circulaton rejuvenates bone repair through modulation of β-catenin,” Nat. Commun., vol. 6, no. May, pp. 1–10, 2015, doi: 10.1038/ncomms8131.

I. M. Conboy, M. J. Conboy, A. J. Wagers, E. R. Girma, I. L. Weissman, and T. A. Rando, “Rejuvenation of aged progenitor cells by exposure to a young systemic environment Irina,” Nature, vol. 433, no. 7027, pp. 760–764, 2005, [Online]. Available: Library/Library.papers3/Articles/2005/Conboy/Nature 2005 Conboy.pdf%0Apapers3://publication/uuid/FCAE9822-AEEE-426B-83D2-FB86BFB6327D.

G. A. Jerrard et al., “Implications of Weight and Body Mass Index for Plasma Donation and Health,” ISRN Hematol., vol. 2012, no. May 2010, pp. 1–5, 2012, doi: 10.5402/2012/937585.

J. Seghatchian and F. Lanza, “Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike,” Transfus. Apher. Sci., vol. 59, no. 3, p. 102794, 2020, doi: 10.1016/j.transci.2020.102794.

D. Focosi, A. O. Anderson, J. W. Tang, and M. Tuccori, “Convalescent plasma therapy for covid-19: State of the art,” Clin. Microbiol. Rev., vol. 33, no. 4, pp. 1–17, 2020, doi: 10.1128/CMR.00072-20.

T. Burnouf and J. Seghatchian, “Ebola virus convalescent blood products: Where we are now and where we may need to go,” Transfus. Apher. Sci., vol. 51, no. 2, pp. 120–125, 2014, doi: 10.1016/j.transci.2014.10.003.

How to Cite
N. Ilmiyah, S. Al Hasani, and D. Renaningtyas, “COMBINATION OF SAW-TOPSIS AND BORDA COUNT METHODS IN SEQUENCING POTENTIAL CONVALESCENT PLASMA DONORS”, BAREKENG: J. Math. & App., vol. 17, no. 3, pp. 1521-1532, Sep. 2023.